Vontobel Holding Ltd. Has $3.46 Million Position in Novavax, Inc. (NASDAQ:NVAX)

Vontobel Holding Ltd. reduced its position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 13.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 430,737 shares of the biopharmaceutical company's stock after selling 67,795 shares during the quarter. Vontobel Holding Ltd. owned about 0.27% of Novavax worth $3,463,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Spire Wealth Management acquired a new stake in shares of Novavax during the 4th quarter valued at $29,000. KBC Group NV lifted its holdings in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 3,917 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 1,598 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Novavax by 3,538.8% in the third quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company's stock valued at $155,000 after purchasing an additional 11,961 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of Novavax in the third quarter valued at $158,000. 53.04% of the stock is owned by institutional investors.

Novavax Stock Performance

Shares of NASDAQ:NVAX traded down $0.10 during midday trading on Thursday, hitting $7.92. 2,975,767 shares of the stock were exchanged, compared to its average volume of 4,182,139. Novavax, Inc. has a 52-week low of $3.81 and a 52-week high of $23.86. The business's fifty day simple moving average is $8.70 and its two-hundred day simple moving average is $10.16. The company has a market capitalization of $1.27 billion, a PE ratio of -3.50, a P/E/G ratio of 2.96 and a beta of 2.14.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $19.00 target price on shares of Novavax in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $17.83.

Insider Buying and Selling

In other Novavax news, Director Rachel K. King sold 4,150 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the transaction, the director now directly owns 14,770 shares of the company's stock, valued at $133,225.40. This represents a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James F. Young sold 5,400 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now directly owns 51,760 shares in the company, valued at $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,150 shares of company stock worth $119,641. Corporate insiders own 1.00% of the company's stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.